Quaranta Luciano, Riva Ivano, Gerardi Chiara, Oddone Francesco, Floriani Irene, Konstas Anastasios G P
Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Adv Ther. 2016 Jun;33(6):959-81. doi: 10.1007/s12325-016-0333-6. Epub 2016 Apr 30.
The ultimate goal of glaucoma management is the preservation of patients' visual function and quality of life (QoL). The disease itself as well as the medical or surgical treatment can have an enormous impact on a patient's QoL. Even the mere diagnosis of a chronic, irreversible, potentially blinding disorder can adversely affect the patient's sense of well-being and QoL by eliciting significant anxiety. Patients with primary open-angle glaucoma rarely present with visual symptoms, at least early in the course of the disease. A better understanding of patient-reported QoL can improve patient-physician interaction and enhance treatment adherence by customizing treatment options based on individual patient profile, thus optimizing long-term prognosis. These aspects are summarized and critically appraised in this article.
青光眼治疗的最终目标是保留患者的视功能和生活质量(QoL)。疾病本身以及药物或手术治疗都会对患者的生活质量产生巨大影响。仅仅是诊断出一种慢性、不可逆、有潜在致盲风险的疾病,就可能引发严重焦虑,从而对患者的幸福感和生活质量产生不利影响。原发性开角型青光眼患者很少出现视觉症状,至少在疾病早期如此。更好地了解患者报告的生活质量,可以改善医患互动,并通过根据患者个体情况定制治疗方案来提高治疗依从性,从而优化长期预后。本文将对这些方面进行总结和批判性评价。